Chemed Corp. (NYSE:CHE) had its price target increased by Oppenheimer Holdings, Inc. from $200.00 to $220.00 in a report issued on Thursday. The firm presently has an “outperform” rating on the stock. Oppenheimer Holdings, Inc.’s price objective indicates a potential upside of 10.01% from the company’s current price. Oppenheimer Holdings also issued estimates for Chemed Corp.’s Q4 2017 earnings at $2.23 EPS, Q1 2018 earnings at $1.95 EPS, Q2 2018 earnings at $2.09 EPS, Q3 2018 earnings at $2.14 EPS and FY2018 earnings at $8.61 EPS.
Several other equities research analysts have also issued reports on CHE. TheStreet lowered shares of Chemed Corp. from a “b+” rating to a “c+” rating in a report on Tuesday. Royal Bank Of Canada reissued a “hold” rating and issued a $208.00 target price on shares of Chemed Corp. in a report on Wednesday, July 5th. Zacks Investment Research lowered shares of Chemed Corp. from a “buy” rating to a “hold” rating in a report on Tuesday, May 2nd. Finally, BidaskClub lowered shares of Chemed Corp. from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 22nd. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $218.00.
Chemed Corp. (NYSE:CHE) traded down 0.73% during trading on Thursday, hitting $199.98. 140,099 shares of the stock were exchanged. The company has a 50-day moving average price of $204.65 and a 200 day moving average price of $189.96. The firm has a market capitalization of $3.20 billion, a price-to-earnings ratio of 49.61 and a beta of 1.15. Chemed Corp. has a 1-year low of $130.05 and a 1-year high of $216.01.
Chemed Corp. (NYSE:CHE) last released its quarterly earnings results on Tuesday, July 25th. The company reported $2.15 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.89 by $0.26. The firm had revenue of $415.06 million during the quarter, compared to analyst estimates of $407.56 million. Chemed Corp. had a net margin of 4.16% and a return on equity of 26.18%. The business’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.80 EPS. Equities analysts predict that Chemed Corp. will post $8.14 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece of content was published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://stocknewstimes.com/2017/07/29/chemed-corp-che-pt-raised-to-220-00.html.
In related news, Director George J. Walsh III acquired 1,000 shares of the business’s stock in a transaction on Monday, June 26th. The stock was acquired at an average cost of $204.56 per share, with a total value of $204,560.00. Following the acquisition, the director now directly owns 7,908 shares in the company, valued at approximately $1,617,660.48. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Kevin J. Mcnamara sold 4,000 shares of the stock in a transaction that occurred on Tuesday, May 2nd. The shares were sold at an average price of $205.11, for a total transaction of $820,440.00. Following the sale, the insider now directly owns 148,943 shares of the company’s stock, valued at $30,549,698.73. The disclosure for this sale can be found here. Insiders sold a total of 5,400 shares of company stock valued at $1,104,850 over the last three months. 5.32% of the stock is currently owned by insiders.
A number of large investors have recently made changes to their positions in the stock. Teachers Advisors LLC raised its stake in shares of Chemed Corp. by 2.6% in the fourth quarter. Teachers Advisors LLC now owns 29,537 shares of the company’s stock worth $4,738,000 after buying an additional 744 shares during the period. Private Trust Co. NA bought a new stake in shares of Chemed Corp. during the first quarter worth about $455,000. Parametrica Management Ltd bought a new stake in shares of Chemed Corp. during the first quarter worth about $352,000. Louisiana State Employees Retirement System raised its stake in shares of Chemed Corp. by 1.5% in the first quarter. Louisiana State Employees Retirement System now owns 6,600 shares of the company’s stock worth $1,206,000 after buying an additional 100 shares during the period. Finally, Boston Advisors LLC bought a new stake in shares of Chemed Corp. during the first quarter worth about $1,906,000. 98.57% of the stock is owned by institutional investors and hedge funds.
About Chemed Corp.
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.
